Eagle Genomics, based in Cambridge, UK, provides expert bioinformatics consultancy and products across a wide range of commercial sectors. With significant experience in human health and having worked with many of the world’s biggest pharmaceutical companies, Eagle is able to provide efficient and cost-effective solutions that can significantly improve research.
Eagle’s executive management team are a team of top bioinformaticians, whose achievements include leadership roles in a number of leading open-source bioinformatics projects that have defined the way in which research in the field proceeds.
Joining them on the board are some of Cambridge’s best business minds with many years combined experience in growing startup companies into major global organisations. Together, the combination of scientific expertise with sharp business thinking, has helped Eagle establish itself as a respected and innovative company within the biotechnology and bioinformatics sectors.
Chief Executive Officer
As Executive Chairman and CEO, Anthony has built and exited a number of intellectual property rich B2B software companies. In particular, he was responsible for the turnaround, strategic repositioning and sale of private venture backed communications software company, Psytechnics to US Nasdaq listed NetScout. Similarly, as Managing Director of MetaSolv, he was responsible for doubling the size of the European business, prior to that company being acquired by Oracle. In addition to his extensive operational experience, Anthony has occupied every seat at the board table: Chairman, CEO, CFO, NXD and Investor Director (for both public and private companies) and is uniquely qualified in working with CEO’s and their management teams to meet the most significant challenges that they will encounter on their journey.
Chief Product Officer & Founder
With more than 12 years of bioinformatics experience and a scientific background in molecular biology and immune-virology (PhD from the Pasteur Institute, France), Abel first mastered bioinformatics tools and code in the early 90s whilst working on viral phylogenetic studies. After his PhD, he joined the effort at Genoscope (Evry, France), in ramping up the human genome project, putting in place the automatic gene annotation system for human chromosome 14. In 2001, Abel moved to the European Bioinformatics Institute (Cambridge, UK) where he led the Ensembl comparative genomics team until 2007. He founded Eagle shortly before graduating from the Cambridge Judge Business School MBA program in 2008.
Chief Financial Officer
Chris is a Chartered Accountant with some 20 years’ experience of operating in the high technology sector. As Finance Director and CFO respectively, Chris was involved in the sale of Kapiti Limited to Misys plc in 1994 and Psytechnics Limited to Netscout Systems (NASDAQ: NTCT) in 2011.
He has been involved in numerous funding events particularly with Cambridge Broadband Networks where he was CFO for 6 years and at Psytechnics where he was CFO for 5 years. He has led many commercial negotiations with companies such as Microsoft, BT, AT&T and JP Morgan Chase. He has a BSc in Economics with Statistics from Bristol University.
Chief Technology Officer
Radouane has an extensive experience in leading world-class software and data-intensive system developments in different industries from Telecom to Healthcare, Nuclear, Automotive, Financials. Radouane is Lean/Six Sigma Master Black Belt with speciality in high-tech, IT and Software engineering and he is recognised as the leader and early adaptor of Lean/Six Sigma and DFSS to IT and Software. He is a fellow of the Royal Statistical Society (RSS) and member of the ISO Technical Committee (TC69: Applications of Statistical methods) where he is co-author of the Lean & Six Sigma Standard (ISO 18404) as well as the new standard under development (Design for Six Sigma). He is also part of the newly formed international Group on Big Data (nominated by BSI as the UK representative/expert). Radouane has also been Chair of the working group on Measurement Systems for Automated Processes/Systems within the ISPE (International Society for Pharmaceutical Engineering).
Cliff is CEO and Founder of Excelicare, which provides a cloud-based, open platform to facilitate the paradigm shift to a patient-centric model for healthcare. He has held a number of positions at IBM and executive positions at Cisco, Apple, CA Technologies and Allscripts.
Andrew joined specialist venture capital fund manager Midven in 2004. He is a Director of the company and Fund Principal of the Rainbow Seed Fund, which works closely with leading UK publicly funded laboratories. After an initial scientific career in advanced materials at ICI and Zeneca he went on to roles in research and business development at the medical device company Biocompatibles and then became Vice President of Technology for disinfection technology company Sterilox (now Puricore). He started his career in venture capital with the Invention and Innovation seed capital fund at NESTA (the National Endowment for Science Technology and the Arts). Andrew has a degree and a PhD in Chemistry from the University of Oxford.
Vernon practised as a Medical Officer in the Royal Navy before joining the pharmaceutical industry and becoming Medical Director. Following an MBA at Wharton Business School in the USA he worked as management consultant, carrying out a range of assignments. In 1994, he established the Harten Group, which has gained a first class reputation among key industry players for its proactive approach, rapid provision of high calibre consultants from its 2000-strong network, outstanding contacts and in-depth knowledge of the global pharmaceutical and biotech industries. A committee member of BRAPP, Vernon is actively involved in healthcare training for the pharmaceutical industry. His interest in education and training has led to his mentoring role within the Prince’s Trust and The Duke of Edinburgh’s Award.
Simon Thorpe is an angel investor in UK companies with a focus on the technology sector. His current portfolio consists of 20 companies and to date he has achieved four exits, including that of SwiftKey to Microsoft. Simon is an active promoter of the digital economy and was voted UKBAA’s Angel Investor of the year 2016/17.